Bharat Biotech’s Intranasal Vaccine Proven Safe in Clinical Trials


Content Team
Image Credit: Pixabay

Vaccine-maker Bharat Biotech announced on Monday that its intranasal vaccine for Covid-19 has been proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. The Hyderabad-based company completed clinical development for phase III trials and booster doses for BBV154 (intranasal vaccine).